HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- CAR T-cell therapy approval huge step for oncology, but only ‘beginning of story’
-
- Toxicities associated with immunotherapy warrant ‘very high level of suspicion’
- Atezolizumab plus bevacizumab and chemotherapy extends PFS in non-small cell lung cancer
- City of Hope names director of pharmaceutical initiatives
- Gene therapy results in long-term normalization of factor VIII activity in severe hemophilia A
- Genetic markers combined with family, clinical history may be next breast cancer ‘breakthrough’
- Icahn School of Medicine at Mount Sinai appoints chair of geriatrics, palliative medicine
- Karmanos Cancer Institute president elected to Association of American Cancer Institutes board
- Leukemia & Lymphoma Society provides $46 million for research
-
- MedStar Georgetown Cancer Institute appoints director
- Multinational study to compare three regimens for first-line treatment of advanced renal cell carcinoma
- NewYork-Presbyterian/Columbia University Medical Center appoints breast surgery chief
- Novel microscope shows potential for scanning tumors during surgery, assessing biopsies
- Rutgers Cancer Institute names chief surgical officer
- Task force ‘got it right’ with revised prostate cancer screening recommendation
- Task force maintains recommendation against ovarian cancer screening
- Task force recommends against thyroid cancer screening in asymptomatic adults
-
- The Ohio State University Comprehensive Cancer Center appoints interim director
- Yale School of Medicine appoints chair of surgery department
- Obesity and cancer: Beware the festive season Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- FDA approves dasatinib for children with Philadelphia chromosome-positive chronic myeloid leukemia
- FDA approves Adcetris for primary cutaneous anaplastic large cell lymphoma
- FDA approves Alecensa for ALK-positive metastatic non-small cell lung cancer
- FDA approves Mvasi, first biosimilar for cancer
- FDA approves Zelboraf for BRAF V600-mutated Erdheim-Chester disease
-
- Initial assessment of nasopharyngeal carcinoma: Added value of PET/MRI Munir Ghesani, MD, FACNM; Ana M. Franceschi, MD; Elcin Zan, MD
- End-of-life discussions held at ‘astounding’ infrequency
- First-line nivolumab fails to extend PFS in non–small cell lung cancer
- Gefitinib shows activity in advanced esophageal cancer subgroup
- ‘Isolation bag’ trial renews debate about power morcellation
- Non-Hodgkin lymphoma survivors with pre-existing cardiovascular conditions have increased heart failure risk
- Researchers define cancer risk in BRCA1/BRCA2 carriers
- Stage at diagnosis drives racial, ethnic disparities in cancer survival
-
- Adjuvant chemotherapy with accelerated radiotherapy effective for high-risk soft tissue sarcoma
- Cediranib active in alveolar soft part sarcoma
- Adjuvant vemurafenib confers clinical benefit in resected BRAF V600-positive melanoma
- AIM regimen extends PFS, OS in soft tissue sarcoma
- Cabozantinib induces promising response rate for soft tissue sarcoma
- Childhood cancer survivors experience fewer severe health problems
- Dose-dense adjuvant chemotherapy reduces breast cancer mortality
- Effective lung cancer treatment requires precision medicine
-
- Extended adjuvant therapy fails to improve outcomes in hormone receptor-positive breast cancer
- Genomic testing should be used judiciously in early-stage breast cancer
- High compliance with Optune linked to greatest survival benefit for glioblastoma
- Immunotherapy combination ‘new standard of care’ in metastatic renal cell carcinoma
- Local treatment preferred option for brain metastases from renal cell carcinoma
- Location of bone metastasis may affect outcomes in metastatic renal cell carcinoma
- Long-term trabectedin therapy well tolerated for soft tissue sarcoma
- More clinical trials needed in metastatic colorectal cancer
-
- Needle tract recurrence uncommon after core needle biopsy for retroperitoneal sarcoma
- Nivolumab superior to everolimus for pretreated advanced renal cell carcinoma
- Novel therapy shows encouraging disease control for gastrointestinal stromal tumors
- Olaparib significantly prolongs PFS in metastatic BRCA–related breast cancer
- Oncologists must be prepared to inform patients about risks, benefits of CAR T-cell therapies
- Online symptom reporting may help patients with cancer live longer
- Radiotherapy does not reduce mortality, local recurrence in resected sacral chordoma
- Richard Pazdur, MD: FDA tasked with protection of patients, promotion of their concerns
-
- Secondary data analysis offers ‘high-impact’ approach to improving patient care
- Morphology, grading may determine treatment approach in synovial sarcoma
- Surgical margins predict survival in primary pleomorphic liposarcoma
- Crizanlizumab reduces sickle cell–related pain crises
- Do enough data exist to properly screen and monitor patients for toxicities associated with immunotherapies?